Grapiprant is under clinical development by RaQualia Pharma and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Grapiprant’s likelihood of approval (LoA) and phase transition for Colorectal Cancer took place on 11 Nov 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Grapiprant Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Grapiprant (RQ-0000007, RQ-7, MR10A7) is under development for the treatment of hepatocellular carcinoma, triple negative/inflammatory breast cancer, non small cell lung cancer, cancer pain, osteoarthritis pain,metastatic colorectal cancer, esophageal cancer, gastric cancer, head and neck cancer, chronic pain, osteoarthritis pain, post-operative pain, tumors including liver cancer, colorectal cancer, breast cancer, non-small cell lung cancer adenocarcinoma and gastroenterological cancer, autoimmune disorders and allergies. It is administered intravenously and orally. RQ-0000007 (MR10A7) acts by targeting EP4 receptor.
It was also under development for the treatment of non-small cell lung cancer.
RaQualia Pharma overview
RaQualia Pharma (RaQualia) is a drug development company that discovers and develops pharmaceutical compounds. The company’s product portfolio includes ziprasidone, 5-HT2B antagonist, motilin receptor agonist, potassium-competitive acid blockerand 5-HT4 partial agonist. Its products are used in the treatment of gastroparesis, chronic constipation, neuropathic pain, anorexia associated cancer, chronic inflammatory pain and others. RaQualia also offers licensing of intellectual properties for pharmaceutical compounds. The company partners with universities, public research institutions, pharmaceutical companies, bio-venture firms and contract research organizations. RaQualia is headquartered in Nakamura, Nagoya, Japan.
Quick View Grapiprant LOA Data
|Highest Development Stage|